PVI
INDP icon

Pine Valley Investments’s Indaptus Therapeutics INDP Stock Holding History

Pine Valley Investments’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,563
Closed -$24.1K – 584
2025
Q1 		$24.1K Sell
1,563
-6
-0.4% -$138 ﹤0.01% 536
2024
Q4 		$37K Sell
1,569
-2
-0.1% -$64 ﹤0.01% 513
2024
Q3 		$54.5K Sell
1,571
-3
-0.2% -$147 ﹤0.01% 507
2024
Q2 		$93.5K Sell
1,574
-3
-0.2% -$199 0.01% 468
2024
Q1 		$98.9K Sell
1,577
-3
-0.2% -$160 0.01% 470
2023
Q4 		$77.9K Hold
1,580
– – 0.01% 476
2023
Q3 		$122K Sell
1,580
-6
-0.4% -$405 0.01% 445
2023
Q2 		$84.8K Hold
1,586
– – 0.01% 405
2023
Q1 		$89.7K Buy
+1,586
New +$74.9K 0.01% 289

Other funds holding INDP

SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pine Valley Investments's INDP Position: Q2 2025 in Review

Pine Valley Investments sold out of Indaptus Therapeutics (INDP) in Q2 2025, closing a stake of 1,563 shares — an estimated $24.1K sold.

Pine Valley Investments first reported a position in INDP in Q1 2023 and held it in 9 quarters. The position peaked at $122K in Q3 2023. 5 funds tracked by Wall St. Rank hold INDP as of Q2 2025.

  • Pine Valley Investments reported no remaining Indaptus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Pine Valley Investments sold 1,563 Indaptus Therapeutics shares in Q2 2025, an estimated $24.1K.
  • Pine Valley Investments first reported a position in Indaptus Therapeutics in Q1 2023 and held it in 9 quarters.
  • Pine Valley Investments's Indaptus Therapeutics position peaked at $122K in Q3 2023.
  • 5 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2025.

Based on Pine Valley Investments's 13F filing for Q2 2025, filed 17 Feb 2026.